Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 14 Sep 2023 Form 3 Insider Report for RayzeBio, Inc.

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol
N/A
Transactions as of
14 Sep 2023
Net transactions value
$0
Form type
3
Filing time
14 Sep 2023, 19:51:23 UTC
Next filing
19 Sep 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RYZB Series D Preferred Stock 14 Sep 2023 Common Stock 1,557,846 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D Preferred Stock is convertible into one share of the Issuer's Common Stock at any time at the holder's election. Upon the closing of the Issuer's initial public offering, all such shares of Series D Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3. The Series D Preferred Stock has no expiration date.